Synendos Therapeutics
Innovation in Neuroscience
One billion of us around the world are silently struggling, living with mental health conditions that impact our every thought, feeling, every day.
Each year, eight million lives end too soon, with an average of 10 years of life stolen. The cost isn't just measured in the $5 trillion global economic burden, but in dreams deferred, relationships fractured and potential never realized.
8 Million
Lives lost annually with 10 years of life stolen
1 Billion
People affected by mental health conditions worldwide
$5 Trillion
Global economic burden of mental health disorders
The Burden of Mental Health Conditions
At Synendos, we develop new therapies to treat neuropsychiatric disorders at the root cause, not just the symptoms.
Synendos is a clinical-stage neuroscience company targeting the Endocannabinoid System to restore the brain's natural functioning. Our immediate focus is on anxiety- and mood-related disorders, particularly conditions like General Anxiety Disorder (GAD) and Post-Traumatic Stress Disorder (PTSD), where endocannabinoid deficiency contributes to suffering, and treatment options fall short.
Our goal quite simply is to give patients their lives back – at home, at work and in society.